Key Highlights
- It has identified distribution partners in “key” export markets.
- Back home, the company plans to double down on its presence with its current portfolio of plasma-derived therapeutics.
- The company’s key products include albumin, intravenous immunoglobulin, rabies immunoglobulin, hepatitis B immunoglobulin and RhD immunoglobulin (anti-D) which it distributes to private hospitals and state hospitals in India.
- "This investment further strengthens PlasmaGen’s position as a long-term partner to healthcare systems and patients, both in India and internationally,” Vinod Nahar, founder and executive chairman of PlasmaGen, said in a statement.
- The company raised ₹225 crore in 2023 in a round led by the UK’s Artian Investments, with participation from public market investor Ashish Kacholia alongside Eight Roads Ventures' India team and F-Prime Capital.
